Ensign Peak Advisors
BCAB icon

Ensign Peak Advisors’s BioAtla BCAB Stock Holding History

Ensign Peak Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-103
Closed -$26K – 2165
2022
Q1 		$26K Hold
103
– – ﹤0.01% 2164
2021
Q4 		$101K Buy
+103
New +$132K ﹤0.01% 2058

Other funds holding BCAB

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors's BCAB Position: Q2 2022 in Review

Ensign Peak Advisors sold out of BioAtla (BCAB) in Q2 2022, closing a stake of 103 shares — an estimated $26K sold.

Ensign Peak Advisors first reported a position in BCAB in Q4 2021 and held it in 2 quarters. The position peaked at $101K in Q4 2021. 76 funds tracked by Wall St. Rank hold BCAB as of Q2 2022.

  • Ensign Peak Advisors reported no remaining BioAtla position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 103 BioAtla shares in Q2 2022, an estimated $26K.
  • Ensign Peak Advisors first reported a position in BioAtla in Q4 2021 and held it in 2 quarters.
  • Ensign Peak Advisors's BioAtla position peaked at $101K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held BioAtla as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.